Luke Halpern, Associate Editor

Incremental, plant-based dietary changes can improve glycemic control, weight, and lipid outcomes while complementing cardiometabolic pharmacotherapy in routine pharmacy practice.

The platform offers uninsured patients discounted drug prices, though it is important to note that the platform does not sell drugs, and only a small number are currently available.

The scientific statement underscores obesity as a complex, socially driven condition and positions pharmacists as key partners in reducing stigma, improving access to care, and supporting equitable weight management.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) was found to reduce the risk of chronic kidney disease (CKD) and key associated factors, like eGFR and albuminuria.

Full results detailing the safety and efficacy of enlicitide decanoate, an oral PCSK9 inhibitor, were published in The New England Journal of Medicine.

During American Heart Month, Sarah Nelson, PharmD, highlights how pharmacists can leverage frequent patient interactions, risk assessment tools, and medication optimization strategies to reduce cardiovascular risk.

Legislation targeting the practices of pharmacy benefit managers (PBMs) was passed by Congress and signed by the president, with the goal of greater transparency and increased pharmacy access.

Joseph Saseen, PharmD, explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

Replacing animal products—particularly processed meats—with plant-based foods, including some processed options, can lower cardiometabolic risk and offer pharmacists practical counseling opportunities alongside medication therapy.

Explore all 16 agreements struck thus far between pharmaceutical companies and the White House to adhere to most favored nation pricing for drugs sold in the United States.

Treatment with semaglutide offers benefits beyond solely cardiovascular risk reduction, lowering the risk of hospitalization across a range of comorbidities.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

Exclusive insights from Ned Milenkovich, PharmD, JD, help parse what pharmacists should be aware of as most favored nation initiatives are agreed upon with the federal government.

On Chen, MD; and Tahmid Rahman, MD, join Pharmacy Focus to discuss the world's first commercial administration of plozasiran at Stony Brook Medicine.

Processed plant-based foods, such as breads and cereals, can reduce the risk of diabetes and heart failure when they replace ultraprocessed meats or sugary beverages.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

Experts say SMS-based engagement tools can help pharmacists improve medication adherence and reduce hospital readmissions by addressing common patient barriers such as forgetfulness and cost.

Cardiotoxic signals released from the kidneys may drive cardiovascular risk in patients with chronic kidney disease, opening the door to earlier detection and targeted treatment.

The American Heart Association (AHA) has released new guidance highlighting numerous obstacles that individuals with obesity face when treating and managing their condition, including limited access to healthy foods and weight stigma.

Explore how radio frequency identification (RFID) technology enhances medication safety, operational efficiency, and patient care in health care and pharmacy settings.

Ben Long, MD, and Weston Blakeslee, PhD, discuss how pharmacists can integrate automated SMS tools to reduce readmissions while minimizing workflow burden.

Patients with chronic kidney disease (CKD) send miRNA extracellular vesicles to the heart, contributing to the pathogenesis of heart failure.

The short message service (SMS) text reminders were targeted toward vulnerable patient populations and consequently reduced rates of readmission to the hospital.

Ann Marie Navar, MD, PhD, explains how enlicitide decanoate delivers LDL-C reductions comparable with injectable PCSK9 inhibitors, which could improve access to nonstatin therapy for patients not at goal.

On Chen, MD, and Tahmid Rahman, MD, explain the real-world safety, dosing advantages, and pharmacist-driven identification strategies for patients who may benefit from plozasiran therapy.

Plozasiran offers a novel RNA-based mechanism to significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome.

Ben Long, MD; and Weston Blakeslee, PhD, explain how personalized text messaging helps overcome common adherence barriers and keeps patients engaged without overwhelming them.

Jeffery Goad, PharmD, MPH, outlines how recent changes to the childhood immunization schedule may affect vaccine confidence, uptake, and public health, while highlighting the essential role pharmacists play in patient education.

Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists were found to offer neuroprotective effects to patients who were administered the medications.